A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

BACKGROUND: In type 2 diabetes mellitus, fixed-dose combination (FDC) can provide the complementary benefits of correction of multiple pathophysiologic defects such as dysfunctions in glycemic or metabolic control while improving compliance compared with separate tablets taken together. The objectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sang-In, Lee, Howard, Oh, Jaeseong, Lim, Kyoung Soo, Jang, In-Jin, Kim, Jeong-Ae, Jung, Jong Hyuk, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324327/
https://www.ncbi.nlm.nih.gov/pubmed/25678778
http://dx.doi.org/10.2147/DDDT.S75980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324327/
https://www.ncbi.nlm.nih.gov/pubmed/25678778
http://dx.doi.org/10.2147/DDDT.S75980

Ejemplares similares